Floatz logo

Docetaxel

Kidney and Urinary Cancer

Sandy SrinivasSmall moleculePhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Kidney and Urinary Cancer cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Region Skane
Phase 4BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Astellas Pharma Global Development, Inc.
Phase 2BB
Abiraterone Acetate
Eli Lilly and Company
Phase 3B
FULVESTRANT
Atavistik Bio, Inc
Phase 2B
VOLITINIB
AstraZeneca
Phase 3B

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →